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Objective: Circulating levels of 25-hydroxyvitamin D (25OHD) are positively associated with high density
lipoprotein (HDL) cholesterol. We sought to replicate a previously reported interaction between APOA5
genotype and vitamin D, and to examine whether HDL-associated genetic loci modify the association
between serum 25OHD and HDL cholesterol.
Methods: We examined whether 42 single nucleotide polymorphisms (SNPs) modify the association
between serum 25OHD and HDL cholesterol in the 1958 British Birth cohort (aged 45 years, n ¼ 4978).
Results:We identiﬁed a borderline interaction between the SNP rs12272004 (near the APOA5) and serum
25OHD on HDL cholesterol (Pinteraction ¼ 0.05). The interaction was particularly prominent among the
samples collected during winter (Pinteraction ¼ 0.001). None of the other loci showed an interaction with
serum 25OHD concentrations on HDL cholesterol.
Conclusions: Our study in 4978 British Whites provides further support that APOA5 genotype modiﬁes the
association between vitamin D metabolites and HDL cholesterol.
 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license .1. Introduction
Cardiovascular disease is one of the leading causes of mortality
in the world [1]. Epidemiological studies have shown an inverse
association between circulating levels of 25-hydroxyvitamin D
(25OHD) and cardiovascular risk factors including lipid proﬁle, in
particular, high density lipoprotein (HDL) cholesterol [2,3]. How-
ever, it is still unclear whether 25OHD concentrations are causally
related to the disease or are just a marker of health or lifestyle [4].
Placebo-controlled randomized trials that examined the effect of
vitamin D supplementation on serum lipids have provided diver-
gent results, with some showing a positive effect while others were
negative [5]. These inconsistencies could possibly be due to un-
identiﬁed interactions between the genes that contribute to vari-
ation in HDL cholesterol and 25OHD concentrations.
A recent genome-wide association study has identiﬁed nearly
95 loci that have been shown to contribute to the normal variation
in lipid traits and also to extreme lipid phenotypes [6]. Of these 95NP, single nucleotide poly-
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cholesterol. A recent study in 1060 individuals from Utah families
used 14 of the most signiﬁcant and replicated lipid loci [6] to
identify possible interactions with dietary vitamin D on lipid levels.
They reported a signiﬁcant interaction between dietary vitamin D
intake and APOA5 SNP rs3135506 on HDL cholesterol levels and
found that the interaction was more signiﬁcant among the winter-
collected samples as compared to the entire sample (p ¼ 0.0004)
[7]. They observed a similar interaction in the replication sample
(n ¼ 2890) [7], where the interaction between dietary vitamin D
and APOA5 on HDL cholesterol was stronger among the winter-
collected samples as compared to the entire sample (p ¼ 0.002).
However, in another replication sample (n ¼ 1552) [7], where
serum 25OHD concentrations were used instead of dietary vitamin
D, interaction was not observed.
In line with the hypothesis that genes inﬂuence HDL cholesterol
levels in response to vitamin D intake, we expanded the study to
investigate geneeenvironment interaction using data from 4978
individuals from the 1958 British Birth Cohort. The two main ob-
jectives of the study include (i) to test whether the APOA5 SNP
rs3135506 interacts with serum 25OHD on HDL cholesterol, and (ii)
to perform explorative evaluation of all other possible interactions
between the other established HDL-related loci [6] and serum
25OHD concentrations on HDL cholesterol levels.
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2.1. Study participants
Study participants are from the 1958 British birth cohort
(1958BC), which initially included all births in England, Scotland,
and Wales during 1 week in March 1958 (n ¼ 16,751) [8]. At age 45
years, 11,971 participants were invited to attend a biomedical sur-
vey: 9377 (78%) completed at least one questionnaire. The 1958BC
is largely awhite European population (98%) and despite some data
attrition, it has been evaluated to be broadly representative of the
surviving cohort [9]. The main analyses were conducted on 4978
participants of European Ancestry with information on the single
nucleotide polymorphisms (SNPs), 25OHD concentrations, and HDL
cholesterol. The 45-year biomedical survey and genetic studies
were approved by the South-East Multi-Centre Research Ethics
Committee (Ref: 01/1/44) and the joint UCL/UCLH Committees on
the Ethics of Human Research (Ref: 08/H0714/40).
2.2. Clinical data collection
Venous blood samples were drawn without prior fasting and
posted to the collaborating laboratory. HDL cholesterol was
measured by standard autoanalyzer methodology. As in a previous
study of lipid measures in the 1958BC [10], HDL cholesterol levels
were corrected to allow for treatment effects amongst those taking
lipid medications (n ¼ 74) prior to the analysis. This was based on
the assumption that commonly prescribed lipid-lowering medica-
tions increase HDL cholesterol by an average of 5%. The 25OHDwas
measured using automated application of an enzyme-linked
immunosorbent assay (IDS OCTEIA ELISA; IDS, Bolton, United
Kingdom) and an analyser (BEP2000; Dade-Behring, Milton
Keynes, United Kingdom) with sensitivity of 5.0 nmol/L, linearity
155 nmol/L, and intraassay CV 5.5e7.2%. The 25OHD concentra-
tions were standardized according to the mean of the values found
by the Vitamin D External Quality Assurance survey (DEQAS) [11].
2.3. SNP selection and genotyping
We selected 47 loci that have been shown to be associated with
HDL cholesterol based on the recently published GWAS [6]. In
addition, we selected the APOA5 SNP rs3135506 based on the study
by Shirts et al., 2012 [7]. The APOA5 SNP rs3135506 was not avail-
able and hence, we used the SNP rs12272004 (near the APOA5),
which is in high linkage disequilibrium (LD, r2¼ 1) [7] with the SNP
rs3135506.Table 1
Interaction between SNP rs12272004 near the APOA5 gene and 25-hydroxyvitamin D con
Cohort (n ¼ 4936).
Season Genotype N % change in
HDL (SE)b
All CC 4295 0.12 (0.01)
AC 616 0.08 (0.04)
AA 25 0.44 (0.15)
Winter-collected samplesd CC 1615 0.09 (0.03)
AC 236 0.11 (0.06)
AA 12 0.79 (0.21)
Summer-collected samplesd CC 1850 0.14 (0.02)
AC 270 0.03 (0.05)
AA 12 0.07 (0.26)
LRT, Likelihood ratio test.
a The natural logarithm was used to transform the skewed HDL cholesterol levels t
geographical region and gender.
b Percentage change in HDL cholesterol for a 1 nmol/L increase in 25-hydroxyvitamin
c Based on difference in adjusted R2 between nested models; R2 for interaction obtain
d Winter is deﬁned as NovembereMarch (Shirts et al.) [7] and Summer is deﬁned as MThe genotype data for the SNPs were obtained from the
genome-wide platforms through two sub-studies [12,13], both
using the 1958BC participants as population controls. The ﬁrst sub-
study included 3000 DNA samples randomly selected as part of the
Welcome Trust Case Control Consortium (WTCCC2) and genotyped
on the Affymetrix 6.0 platform [12]. The second sub-study was the
Type 1 diabetes caseecontrol study (T1DGC) which used 2500 DNA
samples and genotyped using the Illumina Inﬁnium 550K chip
through the JDRF/WT Diabetes and Inﬂammation Laboratory [13].
For SNPs not included in the genome-wide platforms, a proxy
(r2 ¼ 1) or imputed SNP was used for analysis where available.
“Best-guess” genotypes were inferred from the imputed SNP
probabilities using a call threshold of 0.9 [14]. All SNPs included in
the analysis had call rate >95%, imputation quality >0.9, MAF
>0.05, and were in HardyeWeinberg equilibrium (p > 0.01). Six
SNPs (rs13107325, rs581080, rs1883025, rs4759375, rs4420638
and rs2652834) were excluded from the analysis because of low
call rate (<95%) and unavailability of proxy or imputed SNPs. In
total, we used 42 SNPs (41 SNPs selected from Teslovich et al. [6]
and 1 SNP chosen from Shirts et al. [7]) for the present study.2.4. Statistical analyses
The natural logarithm was used to transform the skewed HDL
cholesterol levels to an improved approximation of the normal
distribution. All models were adjusted for sex and region (Scotland
or South, Middle or North of England). Owing to the complex in-
heritance pattern of HDL cholesterol, different genetic models that
could be compatible with the data were tested. Interactions be-
tween each SNP and 25OHD were assessed using linear regression
and the likelihood ratio test. For calculating the percentage of
variation in HDL cholesterol explained by the interaction effect, we
used the adjusted R-squared (R2) from the regression model. A chi-
square goodness of ﬁt test was used to assess deviation from
HardyeWeinberg equilibrium (P > 0.01 for all SNPs). All P values
were derived from two-sided tests. Multiple testing was corrected
for in the exploratory interaction analyses using Bonferroni
method [Pinteraction < 0.00122 (¼ 0.05/41 SNPs) were considered to
be signiﬁcant]. The correction for multiple testing was not applied
for the APOA5 interaction analysis, as it was an independent test for
replication. Due to the postulated effect of season on the strength
of the genetic interaction suggested by the earlier study [7], in-
teractions were also investigated by the time of sample collection
(winter vs summer). Winter was deﬁned as NovembereMarch
(Shirts et al.) [7] and summer was deﬁned as MayeSeptember
(samples collected during April and October were excludedcentrations on high density lipoprotein cholesterol levelsa in the 1958 British Birth
P values for %
change in HDL
Interaction
P-value (LRT)
Percentage (%) of variation in the HDL
cholesterol explainedc
1.2  1017 0.05 Interaction term: 0.07
Genetic main effect: 0.11
25OHD main effect: 1.48
0.03
0.004
1.7  104 0.004 Interaction term: 0.41
Genetic main effect: 0.08
25OHD main effect: 1.21
0.06
1.6  104
1.8  1011 0.13 Interaction term: 0.09
Genetic main effect: 0.18
25OHD main effect: 1.70
0.58
0.80
o an improved approximation of the normal distribution. All models adjusted for
D concentration.
ed from comparison with a model including both main terms.
ayeSeptember.
Table 2
Interaction between HDL-associated loci and 25-hydroxyvitamin D (25OHD) concentrations on high density lipoprotein cholesterol levels in the 1958 British Birth Cohort
(n ¼ 4978).
Gene Gene name SNPs Chromosome
location
Call rate for
genotyping (%)
HWE
P value
MAF P valuesa for the interaction between
SNPs and 25OHD on HDL cholesterolb
All seasons Winter Summer
ABCA1 ATP-binding cassette, sub-family A (ABC1),
member 1
rs1883025d 9q31.1 91.9 0.01 0.24 e e e
ABCA8 ATP-binding cassette, sub-family A (ABC1),
member 8
rs4148008 17q24 99.2 0.28 0.32 0.72 0.19 0.55
AMPD3 Adenosine monophosphate deaminase 3 rs2923084 11p15 100.0 0.15 0.17 0.88 0.58 0.87
ANGPTL4 Angiopoietin-like 4 rs7255436 19p13.3 99.8 0.56 0.49 0.78 0.68 0.54
APOA1 Apolipoprotein A-I rs964184 11q23-q24 99.8 1.00 0.13 0.78 0.23 0.26
APOB Apolipoprotein B rs1042034 2p24-p23 99.2 0.61 0.21 0.82 0.38 0.34
APOE Apolipoprotein E rs4420638d 19q13.2 57.7 0.50 0.18 e e e
ARL15 ADP-ribosylation factor-like 15 rs6450176 5p15.2 97.5 0.55 0.25 0.89 0.89 0.71
C6orf106 Chromosome 6 open reading
frame 106
rs2814944 6p21.31 100.0 0.25 0.15 0.15 0.02 (0.66)c 0.97
CETP Cholesteryl ester transfer protein,
plasma
rs3764261 16q21 99.2 0.73 0.33 0.35 0.53 0.36
CITED2 Cbp/p300-interacting transactivator,
with Glu/Asp-rich carboxy-terminal
domain, 2
rs605066 6q23.3 99.7 0.36 0.41 0.84 0.69 0.79
CMIP c-Maf inducing protein rs2925979 16q23 98.9 0.60 0.31 0.94 0.87 0.44
COBLL1 COBL-like 1 rs12328675 2q24.3 99.2 0.69 0.12 0.82 0.65 0.53
FADS1-2-3 Fatty acid desaturase 1 rs174546 11q12.2-q13.1 100.0 0.16 0.34 0.21 0.01 (0.57)c 0.83
GALNT2 UDP-N-acetyl-alpha-D-galactosamine:
polypeptide
N-acetylgalactosaminyltransferase 2
(GalNAc-T2)
rs4846914 1q41-q42 98.6 0.15 0.38 0.46 0.16 0.95
HNF4A Hepatocyte nuclear factor 4, alpha rs1800961 20q13.12 100.0 1.00 0.03 0.02 (0.62)c 0.009 (0.37)c 0.42
IRS1 Insulin receptor substrate 1 rs2972146 2q36 99.7 0.23 0.36 0.70 0.75 0.50
KLF14 Kruppel-like factor 14 rs4731702 7q32.3 99.6 0.14 0.49 0.47 0.76 0.69
LACTB Lactamase, beta rs2652834d 15q22.1 92.8 0.28 0.17 e e e
LCAT Lecithin-cholesterol acyltransferase rs16942887 16q22.1 100.0 0.22 0.12 0.93 0.56 0.94
LIPC Lipase, hepatic rs1532085 15q21-q23 98.2 1.00 0.39 0.11 0.25 0.45
LIPG Lipase, endothelial rs7241918 18q21.1 99.3 0.36 0.18 0.82 0.38 0.35
LOC55908 Chromosome 19 open reading frame 80 rs737337 19p13.2 98.1 0.40 0.07 0.78 0.25 0.53
LPA Lipoprotein, Lp(a) rs1084651 6q26 95.9 0.67 0.16 0.26 0.97 0.20
LPL Lipoprotein lipase rs12678919 8p22 100.0 0.88 0.10 0.60 0.90 0.29
LRP1 Low density lipoprotein
receptor-related protein 1
rs11613352 12q13-q14 100.0 0.06 0.24 0.48 0.44 0.96
LRP4 Low density lipoprotein
receptor-related protein 4
rs3136441 11p11.2 99.7 0.18 0.15 0.68 0.89 0.12
MC4R Melanocortin 4 receptor rs12967135 18q22 99.4 0.88 0.23 0.16 0.21 0.33
MLXIPL MLX interacting protein-like rs17145738 7q11.23 99.6 0.95 0.13 0.90 0.95 0.79
MVK Mevalonate kinase rs7134594 12q24 99.1 0.33 0.47 0.28 0.61 0.18
PABPC4 Poly(A) binding protein,
cytoplasmic 4 (inducible form)
rs4660293 1p34.2 100.0 0.40 0.24 0.27 0.03 (1.00)c 0.21
PDE3A Phosphodiesterase 3A, cGMP-inhibited rs7134375 12p12 95.2 0.31 0.41 0.04 (1.00)c 0.62 0.12
PGS1 Phosphatidylglycerophosphase synthase 1 rs4129767 17q25.3 100.0 0.44 0.49 0.13 0.90 0.35
PLTP Phospholipid transfer protein rs6065906 20q13.12 100.0 0.04 0.18 0.46 0.27 0.43
PPP1R3B Protein phosphatase 1, regulatory
subunit 3B
rs9987289 8p23.1 99.5 0.86 0.09 0.86 0.26 0.64
SBNO1 Strawberry notch homolog 1 (Drosophila) rs4759375d 12q24.31 94.5 0.02 0.05 e e e
SCARB1 Scavenger receptor class B, member 1 rs838880 12q24.31 99.2 0.43 0.31 0.22 0.18 0.04 (1.00)c
SLC39A8 Solute carrier family 39 (zinc transporter),
member 8
rs13107325d 4q22-q24 88.1 0.79 0.06 e e e
STARD3 StAR-related lipid transfer (START)
domain containing 3
rs11869286 17q11-q12 100.0 0.90 0.33 0.42 0.56 0.51
TRIB1 Tribbles homolog 1 (Drosophila) rs2954029 8q24.13 99.1 0.11 0.47 0.43 0.33 0.16
TRPS1 Trichorhinophalangeal syndrome I rs2293889 8q24.12 99.6 0.61 0.43 0.18 0.87 0.18
TTC39B Tetratricopeptide repeat domain 39B rs581080d 9p22.3 87.1 0.52 0.15 e e e
UBASH3B Ubiquitin associated and SH3 domain
containing B
rs7941030 11q24.1 98.6 0.98 0.38 0.43 0.52 0.28
UBE2L3 Ubiquitin-conjugating enzyme E2L 3 rs181362 22q11.21 100.0 0.78 0.19 0.12 0.60 0.01 (0.39)c
ZNF664 Zinc ﬁnger protein 664 rs4765127 12q24.31 100.0 0.02 0.34 0.74 0.29 0.09
ZNF648 Zinc ﬁnger protein 648 rs1689803 1q25.3 100.0 0.81 0.36 0.06 0.36 0.02 (0.90)c
LILRA3 Leukocyte immunoglobulin-like receptor,
subfamily A (without TM domain),
member 3
rs398217 19q13.4 98.6 0.94 0.23 0.78 0.07 0.06
SNP, Single nucleotide polymorphism; MAF, Minor allele frequency; HWE, HardyeWeinberg equilibrium, HDL, High density lipoprotein.
a Results are for the additive models, and all are adjusted for sex and region.
b The natural logarithm was used to transform the skewed HDL cholesterol levels to an improved approximation of the normal distribution.
c P values in brackets are corrected for multiple testing.
d SNPs with an overall call rate <95% were excluded from the analyses (n ¼ 6).
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version 12.
3. Results
3.1. Replication of the interaction between the SNP rs12272004
near the APOA5 gene and 25OHD on HDL cholesterol
In the 1958BC, 25OHD concentrations were associated with HDL
cholesterol (% change in HDL: 0.15, 95%CI: 0.12e0.18,
P ¼ 1.39  1023, adjusted for sex, region and month of measure-
ment) while there was no evidence for an association between the
SNP rs12272004 near the APOA5 gene and HDL cholesterol
(P ¼ 0.13, adjusted for sex, region, and 25OHD).
The SNP rs12272004 showed an interaction (Pinteraction ¼ 0.05)
with 25OHD on HDL cholesterol under an additive model (Table 1).
For every 1 nmol/L increase in 25OHD concentrations, the change in
HDL cholesterol levels was larger amongst those with two minor
(“A”) alleles of the APOA5 SNP (0.44% increase in HDL, p ¼ 0.004)
compared to individuals with either no minor alleles or one minor
allele (0.12% increase in HDL, p ¼ 1.2  1017 and 0.08% increase in
HDL, p¼ 0.03, respectively). The evidence for interactionwas slightly
stronger when tested under a recessive model (taking CC þ AC as
reference, Pinteraction¼ 0.03).We also tested for the interaction based
on the stratiﬁcation of the samples by the month of sample collec-
tion, as performed in the study by Shirts et al., 2012 [7], and found
that the evidence for an interaction was predominantly seen when
restricted to samples collected during winter (Pinteraction ¼ 0.004)
(Table 1). Among the winter-collected samples, for every 1 nmol/L
increase in 25OHD concentrations, the change in HDL cholesterol
level was larger amongst those with two minor alleles of the SNP
(0.79% increase inHDL, P¼ 1.6104) compared to thosewith either
no minor alleles or one minor allele (0.09% increase in HDL,
p ¼ 1.7  104 and 0.11% increase in HDL, P ¼ 0.06, respectively).
3.2. Interaction between the 41 HDL-associated loci and 25OHD on
HDL cholesterol
Before correction for multiple testing, two SNPs, namely PDE3A
SNP rs7134375 and HNF4A SNP rs1800961, showed some evidence
for interaction with 25OHD concentrations on HDL cholesterol
under an additive model (rs7134375, Pinteraction ¼ 0.04; rs1800961,
Pinteraction ¼ 0.02) (Table 2). For HNF4A SNP rs1800961, there was
also evidence for an interaction that was predominantly seen
during the winter (p ¼ 0.009). However, after correction for mul-
tiple testing, none of the interactions were signiﬁcant. Similarly,
under a recessive model, none of the interactions were signiﬁcant
after correction for multiple testing (data not shown).
4. Discussion
Extending from the ﬁndings on earlier study on vitamin D intake
[7], these data suggest that the association between 25OHD con-
centrations and HDL cholesterol levels is stronger amongst those
with two minor alleles of the APOA5 SNP compared to those with
one or less minor allele. Low 25OHD concentrations have been
associated with lipid traits in several studies [5] and are also
associated with metabolic syndrome, with proposed adverse in-
ﬂuences on the risk of cardiovascular disease [15]. These ﬁndings
suggest that the associations between vitamin D status and meta-
bolic conditions are likely to be complex and that, along with other
proposed mechanisms [5], effects that operate via inﬂuences on
HDL cholesterol deserve consideration.
Our data on 4978 individuals from the 1958BC support the
ﬁndings of Shirts et al. [7] suggesting that APOA5 SNP 3135506(Ser / Trp), that is in high LD with rs12272004, might have a
functional effect on the APOA5 protein by interacting with 25OHD,
which is likely to contribute to the variation in the HDL cholesterol
levels. Another ﬁnding from Shirts et al., [7] which was further
conﬁrmed in our study, was the stronger interaction effect seen in
thewinter-collected samples as compared to the entire sample. The
interaction term explained a relatively large proportion of variation
(0.41%) among the winter-collected samples, especially when
compared to values seen for genetic main effects (0.08e0.18%). One
explanation for seeing a stronger effect during winter could be
because of the fact that people are more prone to be vitamin D
deﬁcient in the winter and the deleterious effects of the risk alleles
on HDL cholesterol could be pronounced in those with very low
vitamin D. Also, the use of serum 25OHD concentrations in our
analysis, in contrast to dietary vitamin D that was considered in the
previous study [7], adds importance to our study in extending the
previous ﬁndings.
In addition, we have performed an explorative evaluation of all
possible interactions of the 41 HDL-associated loci with 25OHD
concentrations on HDL cholesterol and have shown that none of the
loci showed a signiﬁcant interaction after correction for multiple
testing. Overall there was very little evidence for further genetic
inﬂuences on the 25OHD association with HDL. Somewhat
intriguingly, also, HNF4A appeared to inﬂuence the association only
in samples collected during winter, which is suggestive of the need
to consider seasonal variation in the studies involving vitamin D.
Our sample size was relatively large, however, in the context of our
exploratory testing of a large number of variants, wemay have been
underpowered to detect the association and hence, additional
replication might be of interest. Furthermore, we cannot rule out
the possible interactions that could have been seen with the six
HDL-associated loci, for which the genotype data was not available
due to low call rate.
5. Conclusions
There are still very few studies examining geneeenvironmental
interaction, and replicated ﬁndings suggesting modiﬁcation by
diet-related factors (such as 25OHD) and genes are even sparser.
Together with the previous study on vitamin D intake [7], these
data suggest that genetic inﬂuences maymodify the strength of the
beneﬁcial effect of vitamin D nutrition on HDL cholesterol, which
illustrates the likely complexity of mechanisms underlying the
pathogenesis of cardiovascular- related traits.
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